Electrochemotherapy as palliative treatment in patients with thyroid papillary carcinoma

Grau, Juan J.; Caballero, Miguel; Langdon, Cristóbal; Bernal‐Sprekelsen, Manuel; Blanch, José Luís

doi:10.1016/j.bjorl.2015.05.008

Cited by 5 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although experience is still limited, ECT proved to be effective in maintaining airway patency at the ostomy site [190] . Finally, it was successful in palliating selected patients with skin tumor infiltration from underlying tumors of the parotid [173,176] and thyroid gland [191] . In 3 of 4 patients with metastatic papillary thyroid cancer who were resistant to radioiodine and sorafenib, ECT led to stabilization of local disease until death.…”

Section: Head and Neck Cancermentioning

confidence: 99%

“…Several solid organ and hematologic neoplasms can metastasize to the skin, with an overall incidence of 0.7-10% [225][226][227] . ECT has been occasionally investigated to palliate patients with lung, gastric, bladder, and kidney cancer [11,191,200,228,229] . However, because the evidence relies on isolated reports, any possible clinical benefit must be carefully evaluated on an individual basis.…”

Section: Skin Metastases From Visceral Malignanciesmentioning

confidence: 99%

See 1 more Smart Citation

Electrochemotherapy of superficial tumors – Current status:

Campana

Miklavčič

Bertino

et al. 2019

Seminars in Oncology

View full text Add to dashboard Cite

Section: Head and Neck Cancermentioning

confidence: 99%

Section: Skin Metastases From Visceral Malignanciesmentioning

confidence: 99%

Electrochemotherapy of superficial tumors – Current status:

Campana

Miklavčič

Bertino

et al. 2019

Seminars in Oncology

View full text Add to dashboard Cite

“…5 Although these treatments have been constantly improved, PTC patients still suffer from cancer recurrence, invasion and/or metastasis. 6 Therefore, developing more effective methods of diagnosis and treatment for managing PTC is highly necessary.…”

Section: Introductionmentioning

confidence: 99%

<p>Knockdown of <em>LINC02471</em> Inhibits Papillary Thyroid Carcinoma Cell Invasion and Metastasis by Targeting miR-375</p>

Chen

Huang

Ning

et al. 2020

CMAR

View full text Add to dashboard Cite

Background: LncRNAs play important roles in papillary thyroid carcinoma (PTC). LINC02471 has been reported to be related to PTC prognosis. The current study aimed to investigate the effects of LINC02471 on human PTC cells. Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to examine LINC02471 expression in PTC tissues and cells and miR-375 expression in PTC cells. SiLINC02471, miR-375 mimic and miR-375 inhibitor were used for cell transfection. Cell proliferation, apoptosis, migration, and invasion were detected by performing Cell Counting Kit-8 (CCK-8), clone formation assay, flow cytometry, scratch assay, and transwell assay. Western blot was carried out to detect protein levels of E-cadherin, N-cadherin and Snail. The target gene for LINC02471 was verified by dual-luciferase reporter assay. Results: LINC02471 was highly expressed in PTC tissues and cells. After silencing LINC02471, cell proliferation, migration and invasion were reduced, but cell apoptosis was increased. SiLINC02471 increased the expressions of E-cadherin and miR-375, and inhibited the expressions of N-Cadherin and Snail. LINC02471 directly targeted miR-375 in PTC cells. Overexpression of miR-375 inhibited the proliferation, migration, invasion of PTC cells and reduced the expressions of N-Cadherin and Snail but promoted the cell apoptosis and increased E-cadherin expression, while miR-375 inhibitor produced opposite effects to overexpressed miR-375. After inhibiting miR-375 expression, siLINC02471 reversed the effect of miR-375 inhibitor. Conclusion: LINC02471 could promote the development of PTC. Knocking down LINC02471 could inhibit invasion and metastasis and promote PTC cell apoptosis through directly targeting miR-375.

show abstract

“…The vast majority of thyroid cancers of follicular origin have a very favorable outcome, but 5-10% of the cases will develop metastatic disease [1]. The most common sites of metastatic differentiated thyroid cancer are the neck lymph nodes, lungs, bones, and less frequently the brain [2]. The skin is an uncommon metastatic site of thyroid cancer but, when it occurs, the scalp is the most frequent region involved [2,3].…”

Section: Introductionmentioning

confidence: 99%

“…The most common sites of metastatic differentiated thyroid cancer are the neck lymph nodes, lungs, bones, and less frequently the brain [2]. The skin is an uncommon metastatic site of thyroid cancer but, when it occurs, the scalp is the most frequent region involved [2,3]. Cutaneous metastases may cause pain, ulceration, and bleeding as well as anxiety due to the awareness of tumor growth [4].…”

Section: Introductionmentioning

confidence: 99%

Palliative Electrochemotherapy Treatment of Cutaneous Metastases in a Patient with Advanced Thyroid Papillary Carcinoma

Cavaco¹,

Carvalhal²,

Leite³

2020

Eur Thyroid J

View full text Add to dashboard Cite

Electrochemotherapy (ECT) is a minimally invasive oncologic treatment of tumors located in the skin and subcutaneous tissue and is highly effective especially to relieve pain, stop bleeding, and improve the quality of life. • Metastatic papillary thyroid carcinoma (PTC) with cutaneous metastases may cause pain, ulceration, and bleeding. Novel Insights• ECT seems to be a safe and effective technique and may be an option for local palliative treatment in cutaneous metastases of PTC with improvement of local symptoms. AbstractAdvanced papillary thyroid carcinoma (PTC) with cutaneous metastases may cause pain, ulceration, and bleeding. Electrochemotherapy (ECT) is a minimally invasive treatment of tumors located in the skin and subcutaneous tissue. The electric pulses potentiate the toxicity of cytostatic agents en-tering the tumor cell. It is highly effective especially to relieve pain and improve the quality of life. The adverse events are local and transient. A case of progressive metastatic PTC who developed bleeding cutaneous metastases treated with ECT is described.

show abstract

Electrochemotherapy as palliative treatment in patients with thyroid papillary carcinoma

Abstract: ECT may be an option for local palliative treatment in PTC patients with local tumor progression.

Cited by 5 publications

References 16 publications

Electrochemotherapy of superficial tumors – Current status:

Electrochemotherapy of superficial tumors – Current status:

<p>Knockdown of <em>LINC02471</em> Inhibits Papillary Thyroid Carcinoma Cell Invasion and Metastasis by Targeting miR-375</p>

Palliative Electrochemotherapy Treatment of Cutaneous Metastases in a Patient with Advanced Thyroid Papillary Carcinoma

Contact Info

Product

Resources

About